Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, one-arm, phase II clinical study of Tislelizumab Combined With
Anlotinib and Chemotherapy for Second-line Treatment of Advanced or Metastatic Pancreatic
Cancer
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University